Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems, Inc.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Delcath Systems yesterday and set a price target of $32.00. The company’s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DCTH	$16.08	+0.75%	276.45K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DCTH	$16.08	+0.8%	276.45K
3
4
5
6

DCTH

Get Delcath Systems, Inc. Data in Excel

Get Delcath Systems, Inc. Data in Excel